[PDF][PDF] Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

BGM Durie, RA Kyle, A Belch, W Bensinger… - The Hematology …, 2003 - Citeseer
MYELOMA MANAGEMENT GUIDELINES A CONSENSUS REPORT FROM THE SCIENTIFIC
ADVISORS OF THE INTERNATIONAL MYELOMA FOUNDATION Page 1 MYELOMA …

Hyperviscosity syndrome in plasma cell dyscrasias

J Mehta, S Singhal - Seminars in thrombosis and hemostasis, 2003 - thieme-connect.com
Hypergammaglobulinemia increases serum viscosity and is the most common cause of
hyperviscosity syndrome. Monoclonal hypergammaglobulinemia resulting in hyperviscosity …

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw

BJ Edwards, M Gounder, JM McKoy, I Boyd… - The lancet …, 2008 - thelancet.com
More than half of all serious adverse reactions are identified 7 or more years after a drug
receives approval from the US Food and Drug Administration (FDA). In 2002, 9 months after …

[HTML][HTML] Antitumor activity of thalidomide in refractory multiple myeloma

S Singhal, J Mehta, R Desikan, D Ayers… - … England Journal of …, 1999 - Mass Medical Soc
Background Patients with myeloma who relapse after high-dose chemotherapy have few
therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in …

[HTML][HTML] A phase 2 study of bortezomib in relapsed, refractory myeloma

PG Richardson, B Barlogie, J Berenson… - … England Journal of …, 2003 - Mass Medical Soc
Background Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has
been shown in preclinical and phase 1 studies to have antimyeloma activity. Methods In this …

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari… - The Lancet, 2016 - thelancet.com
Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …

[PDF][PDF] Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

PG Richardson, H Briemberg, S Jagannath, PY Wen… - J Clin Oncol, 2006 - Citeseer
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of
Advanced Multiple Myeloma With Bortez Page 1 Frequency, Characteristics, and Reversibility …

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

M Dimopoulos, R Kyle, JP Fermand… - Blood, The Journal …, 2011 - ashpublications.org
A panel of members of the 2009 International Myeloma Workshop developed guidelines for
standard investigative workup of patients with suspected multiple myeloma. Both serum and …

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

JA Zonder, AF Mohrbacher, S Singhal… - Blood, The Journal …, 2012 - ashpublications.org
This multicenter, first-in-human study evaluated the safety, tolerability, and pharmacokinetic
and pharmacodynamic properties of the anti-CS1 monoclonal antibody elotuzumab. A …

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

S Lonial, EK Waller, PG Richardson, S Jagannath… - Blood, 2005 - ashpublications.org
Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with
thrombocytopenia, the cause and kinetics of which are different from those of standard …